Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel vs Cilostazol in Large-vessel Ischemic Stroke
NCT06242145Phase 3Completed
- Sponsor
- Kafrelsheikh University
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cilostazol in ischemic stroke (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Rate of new stroke at 90 days and Rate of drug-related hemorrhagic complications at 90 days. Started Jan 2023; status: completed.
02
Drugs
cilostazol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06242145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242145.